The EAHP Board, elected for three-year terms, oversees the association’s activities. Comprising directors responsible for core functions, it meets regularly to implement strategic goals. Supported by EAHP staff, the Board controls finances, coordinates congress organization, and ensures compliance with statutes and codes of conduct.
Dr Katri Hämeen-Anttila
Affiliation:Finnish Medicines Agency (FIMEA) Country:Finland |
1. Current Status, Position
Dr Katri Hämeen-Anttila is currently the Head of Research and Development in the Finnish Medicines Agency (FIMEA), where she leads the research and development team. Research projects are conducted, by law, within the areas of pharmacoepidemiologic, pharmacoeconomic, and medicines policy research.
2. Education
Dr Hämeen-Anttila studied pharmacy at the University of Kuopio (currently University of Eastern Finland) and became a licensed pharmacist in 1999. In 2006 she obtained a PhD in social pharmacy at the University of Kuopio.
3. Research Area
Dr Hämeen-Anttila’s research focuses on patient perspective on medicine use, strategic development of medicines information, children’s medicine education, and medicine information needs of different patient groups, including patient counselling.
4. Conflict of interest: None